TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16617645

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:400,000 adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline with 1:400,000 adrenaline
Number of subjects: 40
Study: 14599997

Group type: EXPERIMENTAL
Intervention: Tiredness in daily activities (measured by questionnaire surveys)
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Low social participation, poor psychological function, and physical inactivity (risk factors identified)
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Home help, low sense of coherence, and physical inactivity (risk factors identified)
Number of subjects: 1396
Study: 11072443

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa (25 mg carbidopa and 100 mg levodopa, one tablet TID for 1 week, 1 1/2 tablets TID for 1 week, then two tablets TID for 6 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (from a previously reported bupropion smoking cessation trial)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa and Placebo
Number of subjects: 40
Study: 8773860

Group type: EXPERIMENTAL
Intervention: 1 mg.kg-1 ketorolac i.v.
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1.5 mg.kg-1 codeine im
Number of subjects: 64
Study: 1335644

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine lot 1
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine lot 2
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine lot 3
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine lots 1, 2, and 3
Number of subjects: 204
Study: 6138083

Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 mg triazolam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 9 mg alpha-hydroxy midazolam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 mg alpha-hydroxy triazolam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 mg 4-hydroxy triazolam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 6
Study: 31831044

Group type: EXPERIMENTAL
Intervention: Self-learning training on the SOP and checklist (group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interactive discussion panel regarding the SOP and checklist (group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Self-learning course with textbooks (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B and C acceptance questionnaire score
Number of subjects: 80
Study: 30267162

Group type: EXPERIMENTAL
Intervention: Tailored letter containing DXA results and educational osteoporosis brochure
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7749
Study: 26674653

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (capillary oxygen saturation 70-75%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 15
Study: 24161482

Group type: COMPARATOR
Intervention: Control group (20 healthy women matched for age and body mass index)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients with CSX
Number of subjects: 22
Study: 18218055

Group type: EXPERIMENTAL
Intervention: Physiologic occlusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lingualized occlusion
Number of subjects: 18
Study: 15191774

Group type: EXPERIMENTAL
Intervention: Revascularisation (PCI or CABG surgery)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Surgical patients (CABG)
Number of subjects: 301
Study: 11279797

Group type: EXPERIMENTAL
Intervention: Autologous tumor cell vaccines (10 million irradiated tumor cells with various adjuvants, weekly x3 and then monthly x5)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Autologous tumor cell vaccines
Number of subjects: 69
Study: 9644824

Group type: EXPERIMENTAL
Intervention: Concurrent articulation during the serial report task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent tapping during the serial report task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-alternative forced choice tests for memory of pattern configuration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial report task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-choice item recognition task
Number of subjects: 0
Study: 7943302

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (77% VO2max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (62% VO2max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-intensity/Low-intensity exercise (HI/LI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-intensity/High-intensity exercise (LI/HI)
Number of subjects: 10
Study: 3062604

Group type: EXPERIMENTAL
Intervention: Triamterene-containing preparation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 11684372

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg/die for 12 cycles
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo patches for 12 cycles
Number of subjects: 50
Study: 30912708

Group type: EXPERIMENTAL
Intervention: Self-disclosure (factual, cognitive, emotional) with similarity
Number of subjects: 280

Group type: COMPARATOR
Intervention: Self-disclosure (factual, cognitive, emotional) with dissimilarity
Number of subjects: 280
Study: 30199562

Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Wavefront-optimized PRK
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Wavefront-optimized LASIK
Number of subjects: 215

Group type: COMPARATOR
Intervention: All groups (PRK and LASIK)
Number of subjects: 215
Study: 27413741

Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane anesthesia (1 L/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-flow sevoflurane anesthesia (4 L/min)
Number of subjects: 60
Study: 25039401

Group type: EXPERIMENTAL
Intervention: Quarter turn from prone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Supine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Prone
Number of subjects: 54
Study: 23268736

Group type: EXPERIMENTAL
Intervention: Single oral vitamin D3 dose (70,000 IU)
Number of subjects: 61
Study: 19887137

Group type: EXPERIMENTAL
Intervention: ACWY-TT conjugate vaccine
Number of subjects: 508
Study: 17636154

Group type: EXPERIMENTAL
Intervention: Balance exercise group (n=17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Falls prevention education group (n=19)
Number of subjects: 36
Study: 16045141

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous ketamine (0.15 mg kg(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (10 microg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous ketamine
Number of subjects: 90
Study: 12394893

Group type: EXPERIMENTAL
Intervention: Conservative treatment (Group A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Surgical treatment (Group B)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Timed 10-m walk test (Group A)
Number of subjects: 68
Study: 10363198

Group type: COMPARATOR
Intervention: Double therapy (interferon alpha + oral ribavirin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Triple therapy (interferon alpha + oral ribavirin + oral amantadine)
Number of subjects: 20
Study: 8881849

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen patch releasing 50 micrograms oestradiol 24 h-1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study: 2047182

Group type: EXPERIMENTAL
Intervention: Sodium nucleinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diucifon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (calcium gluconate)
Number of subjects: 0
Study: 6258237

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study: 30107449

Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral iron therapy
Number of subjects: 50
Study: 28277403

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 26648450

Group type: EXPERIMENTAL
Intervention: Topical coenzyme Q10-containing formulas
Number of subjects: 0
Study: 25018624

Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 1400
Study: 23053780

Group type: EXPERIMENTAL
Intervention: Single-piece IOL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Three-piece IOL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of ACD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of iris-to-IOL distance
Number of subjects: 40
Study: 19715381

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF) pH 6
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF) pH 7.25
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF) pH 8.5
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 12
Study: 17890356

Group type: COMPARATOR
Intervention: Fixed contrast material dose (120 mL of iohexol 300) at an injection rate of 4.0 mL/sec (Protocol 1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Dose tailored to patient's body weight (2.0 mL/kg) injected over 30 seconds (Protocol 2)
Number of subjects: 78
Study: 14999221

Group type: EXPERIMENTAL
Intervention: PT-141 (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PT-141 (6 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PT-141 (0.3 to 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11146577

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with transdermal estrogen with or without progestogen
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (healthy pre-menopausal and post-menopausal women)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen with and without progestogen
Number of subjects: 64
Study: 9832298

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (2 mg x kg(‐1)) during the acute phase
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral prednisone (2 mg x kg(‐1)) during the acute phase
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral prednisone (2 mg x kg(‐1)) after remission
Number of subjects: 12
Study: 8077885

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1.2 mg day-1 to 2.0 mg day-1 (n = 9)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 21
Study: 2812839

Group type: EXPERIMENTAL
Intervention: 30 g of lactulose
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0 g of lactulose (placebo)
Number of subjects: 12
Study: 779998

Group type: EXPERIMENTAL
Intervention: Oral killed cholera vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral live cholera vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral cholera vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30543266

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hypertonic dextrose (20%) injection
Number of subjects: 31

Group type: COMPARATOR
Intervention: 5% normal saline injection
Number of subjects: 31
Study: 28454576

Group type: EXPERIMENTAL
Intervention: Permethrin-fipronil combination (Effitix®) - treated three times every 4 weeks with a spot-on containing 54.5% permethrin and 6.1% fipronil.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment (Control group B).
Number of subjects: 30
Study: 25175425

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 23293013

Group type: EXPERIMENTAL
Intervention: Baseline MADRS (depressive symptoms)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Baseline QLS (functioning/QOL)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Early improvement in QLS (week 2)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Early improvement in SWN-K (subjective well-being, week 2)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Early improvement in PANSS (symptoms, week 2)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Early improvement in CGI-S (overall clinical status, week 2)
Number of subjects: 522
Study: 21707928

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once a day for 12 weeks
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 18839134

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 3548
Study: 16961291

Group type: COMPARATOR
Intervention: Control group received a combination of 10% glucose, Vitamin C, and Inosine
Number of subjects: 68
Study: 12955254

Group type: EXPERIMENTAL
Intervention: Fluorescent in situ hybridisation for 22q11 deletion
Number of subjects: 64
Study: 11130385

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Chloroquine-proguanil
Number of subjects: 1083
Study: 9412897

Group type: EXPERIMENTAL
Intervention: Calcium salts administration after CPB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium influx during ischemia-reperfusion
Number of subjects: 0
Study: 8331125

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 3108105

Group type: EXPERIMENTAL
Intervention: 250 mg Sorbinil daily for 1 year
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 19
Study: 31907074

Group type: EXPERIMENTAL
Intervention: TANDEM intervention (tailored cognitive behavioural approach) delivered weekly for 6-8 weeks by trained respiratory healthcare professionals
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: TANDEM intervention
Number of subjects: 430
Study: 30031660

Group type: EXPERIMENTAL
Intervention: DXA-derived indicators (excluding percentage of total body fat)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: DXA-derived visceral adipose tissue measures (VAT, VAT/Total fat, visceral-to-subcutaneous fat)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: VAT/Total fat
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: VAT
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Lipodystrophy indicators (Trunk/Legs fat and Android/Gynoid fat)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Trunk/Legs fat
Number of subjects: 1207
Study: 26968809

Group type: EXPERIMENTAL
Intervention: Schema-Based Instruction (SBI)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 806
Study: 25844834

Group type: EXPERIMENTAL
Intervention: BASICS (n = 115)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Assessment-only control (n = 110)
Number of subjects: 225
Study: 24269077

Group type: EXPERIMENTAL
Intervention: Intensive, individual dietary counseling (1 hour per week) and daily oral nutritional supplement (2531 kJ, 33.8 g protein, 2.2 g EPA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intensive, individual dietary counseling
Number of subjects: 61
Study: 22648703

Group type: EXPERIMENTAL
Intervention: Teaching recovery techniques (TRT) intervention; 16 extracurriculum sessions
Number of subjects: 482

Group type: COMPARATOR
Intervention: Normal school-provided support (waitlist control)
Number of subjects: 482
Study: 19938921

Group type: EXPERIMENTAL
Intervention: Past sexual assault perpetration
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Hostility and misperception of women's sexual cues
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Misperception of women's sexual intentions
Number of subjects: 72
Study: 17276552

Group type: EXPERIMENTAL
Intervention: Two-dose hepatitis B immunisation (20 microg HBsAg doses 6 months apart)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Three-dose hepatitis B immunisation (10 microg HBsAg doses at 0, 1, 6 months)
Number of subjects: 384
Study: 12677149

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg/d) for 12 weeks postoperatively
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study: 10819700

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study: 8677636

Group type: EXPERIMENTAL
Intervention: 50 U nHuIFN alpha
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 150 U nHuIFN alpha
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 450 U nHuIFN alpha
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1615132

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (0, 25, 50, 100 micrograms/70 kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6496915

Group type: EXPERIMENTAL
Intervention: Bupivacaine during intravenous regional analgesia
Number of subjects: 52
Study: 3514155

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05 percent ointment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.05 percent ointment
Number of subjects: 130
Study: 28745131

Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention with face-to-face and telephone PA counselling
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study: 27009675

Group type: EXPERIMENTAL
Intervention: Coaxial 1.8 mm Micro‐Incision Cataract Surgery (C‐MICS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard 2.75 mm Incision Cataract Surgery (SICS)
Number of subjects: 30
Study: 25118091

Group type: EXPERIMENTAL
Intervention: Structured assessment instrument for case conferences
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Narrative approach for case conferences
Number of subjects: 360
Study: 24084921

Group type: EXPERIMENTAL
Intervention: CEE plus MPA (0.625 mg/d CEE + 2.5 mg/d MPA)
Number of subjects: 27347

Group type: EXPERIMENTAL
Intervention: CEE alone (0.625 mg/d CEE)
Number of subjects: 27347
Study: 20801233

Group type: EXPERIMENTAL
Intervention: Police-patrolled walking plus social marketing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Police-patrolled walking only intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: General health education only (no-walking intervention)
Number of subjects: 0
Study: 18714249

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-stretch
Number of subjects: 20
Study: 16618262

Group type: EXPERIMENTAL
Intervention: Acetaminophen 250 mg, Aspirin 250 mg, Caffeine 65 mg per tablet (AAC)
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg per tablet (IB)
Number of subjects: 1555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1555
Study: 12701006

Group type: EXPERIMENTAL
Intervention: Three consecutive 1‐minute dilations per session at 1‐minute intervals, at 200 mmHg for the first dilation and 300 mmHg for the second and third (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: One dilation at 200 mmHg for 2 minutes (Group B)
Number of subjects: 43
Study: 10984011

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral estradiol treatment
Number of subjects: 40
Study: 9428032

Group type: EXPERIMENTAL
Intervention: T‐HI (programmable multiband full‐dynamic range compression behind‐the‐ear hearing instrument)
Number of subjects: 34

Group type: COMPARATOR
Intervention: C‐mode (linear amplification mode)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: L‐mode (non-linear amplification mode)
Number of subjects: 34
Study: 1403041

Group type: EXPERIMENTAL
Intervention: Etoposide with high-dose cyclosporine (CsA)
Number of subjects: 16
Study: 3907505

Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oral methotrexate
Number of subjects: 82
Study: 31730666

Group type: EXPERIMENTAL
Intervention: Topical lactic acid gel
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oral metronidazole antibiotic
Number of subjects: 33
Study: 29214863

Group type: EXPERIMENTAL
Intervention: Weight management intervention with 28, 1-hour classes tailored for extremes of the Dietary Guidelines' fat recommendations, including supervised and self-directed exercise sessions over 12 months.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Weight management intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lower fat group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Moderate fat group
Number of subjects: 101
Study: 27317968

Group type: EXPERIMENTAL
Intervention: Oral ketamine (150mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac (150mg daily)
Number of subjects: 40
Study: 25148467

Group type: EXPERIMENTAL
Intervention: Preplanned COD drills (CODG, n = 12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Small-sided games (SSGG, n = 12)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CONG, n = 12)
Number of subjects: 36
Study: 21370309

Group type: EXPERIMENTAL
Intervention: Aromatherapy Massage (AM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 39
Study: 20438378

Group type: EXPERIMENTAL
Intervention: Initial HIV therapy strategies (specific strategies not detailed in the abstract)
Number of subjects: 1357